Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]

Related Keywords

United States , Tobin Schilke , Piper Sandler , Dustins Sjuts , Asset Management Inc , Goldman Sachs Group , Needham Company , Exchange Commission , Revance Therapeutics Inc , Nasdaq , Capstone Investment Advisors , Quest Partners , Partners Asset Management , Revance Therapeutics , Free Report , Management Inc , Investment Advisors , Investment Management , Trexquant Investment , Get Free Report , President Dustin , Visit Holdingschannel , Revance Therapeutics Daily ,